Hormone Therapy
Higher endometrial cancer, hyperplasia rates with conjugated estrogens/bazedoxifene
In the first years of use, women prescribed conjugated estrogens/bazedoxifene vs. estrogen/progestin for menopausal symptoms may have higher rates of endometrial cancer and endometrial hyperplasia but lower breast cancer rates.
Is menopausal hormone therapy linked with dementia risk? Studies offer conflicting views
PHILADELPHIA — The short-term effects of postmenopausal hormone therapies on the vascular system and the brain may differ from long-term effects and could be influenced by HT formulation and administration route, according to a speaker.
Not ‘panacea nor poison’: No long-term cognitive effects of menopausal hormone therapy
PHILADELPHIA — At 10 years of follow-up, women who had been assigned menopausal hormone therapy in the KEEPS study had cognitive function scores similar to those of women assigned placebo, according to a speaker.
Menopausal hormone therapy prescriptions remain low in US
PHILADELPHIA — The number of women aged at least 50 years prescribed hormone therapy for menopause symptoms remains low, particularly for Hispanic women, despite good efficacy and safety, according to a presenter.
Women with obesity report more menopausal symptoms, less relief with HT
PHILADELPHIA — In a small study, more women with obesity reported vasomotor, genitourinary, mood and libido symptoms associated with menopause than their peers without obesity, according to a presenter.
VIDEO: Pearls for prescribing menopausal HT for women with chronic medical conditions
PHILADELPHIA — In this video exclusive, Stephanie Faubion, MD, MBA, FACP, NCMP, IF, provides pearls for use of menopausal hormone therapy by women with chronic conditions.
Reduce morbidity, mortality with hormone therapy for premature menopause
PHILADELPHIA — Hormone therapy for women with premature menopause is underutilized due to fear of adverse effects; however, any risks observed with HT after natural menopause are not applicable to young women, according to a speaker.
VIDEO: CVD risk stratification can be valuable when considering menopausal HT
PHILADELPHIA — In this video exclusive, Cynthia A. Stuenkel, MD, MSCP, talks about selecting therapies for menopausal symptoms for women with a history of cardiovascular disease.
Age, race, education among barriers to receiving menopausal hormone therapy
PHILADELPHIA — Age, race and education are the most prevalent barriers accounting for disparities in the prescription of menopausal HT, according to presenters.
Providers concerned about safety, liability with providing transgender care for youths
State legislation prohibiting gender-confirming medical care for children and adolescents may lead to decreased access as pediatric endocrinology providers expressed concerns about their ability to practice in a survey.